The preservative inhibits the growth of bacteria, which is what allows a sealed multi-dose vial to be entered with a sterile needle repeatedly typically over a 28-day in-use window without the remaining contents losing sterility
Unless and until large, well-designed human trials clarify safety and efficacy, BPC-157 remains an unapproved peptide, subject to regulatory controls and compliance requirements in drug-tested populations
Compared to IGF-1 LR3, BPC-157 does not directly stimulate cell proliferation via IGF-1R but acts indirectly via NO/VEGF pathways distinct use profile.
Nitric oxide pathway modulation: BPC-157 activates nitric oxide synthesis, improving circulation and reducing the inflammatory cascade at injury sites
Owing to its unique structure and mode of action, SS-31 demonstrates potential therapeutic value across cardiovascular diseases, neurodegenerative disorders, kidney injury, and myopathies associated with mitochondrial dysfunction 1-6
The majority are classified as mild